Serotonin transporters, serotonin release, and the mechanism of fenfluramine neurotoxicity

Annals of the New York Academy of Sciences

Volumn 914, Issue , 2000, Pages 172-186

  Baumann, Michael H ^a   Ayestas, Mario A ^a   Dersch, Christina M ^a   Partilla, John S ^a   Rothman, Richard B ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; DOPAMINE; FENFLURAMINE; FLUOXETINE; METHOXYFLURANE; NEUROTRANSMITTER; NOMIFENSINE; PARGYLINE; PAROXETINE; PENTOBARBITAL; RESERPINE; SEROTONIN; SEROTONIN AGONIST; TETRODOTOXIN; TRITIUM; VANOXERINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN SYNAPTOSOME; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG UPTAKE; FOREBRAIN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MICRODIALYSIS; NEUROTOXICITY; NONHUMAN; NUCLEUS ACCUMBENS; PULMONARY HYPERTENSION; RAT; SEROTONIN RELEASE; VALVULAR HEART DISEASE;

ANIMALIA; TRITIUM;

EID: 0033695267     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb05194.x     Document Type: Article

References (60)

1. Valvular heart disease associated with fenfluramine-phentermine
2. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite suppressant drugs
3. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine
4. Long-term effects of p-chloroamphetamine and related drugs on the central serotonergic mechanisms
5. Fenfluramine: Evidence for a neurotoxic action on midbrain and long-term depletion of serotonin
6. d-, l-, and dl-fenfluramine cause long-lasting depletions of serotonin in rat brain
7. Effects of high-dose fenfluramine treatment on monoamine uptake sites in rat brain: Assessment using quantitative autoradiography
8. Effects of repeated fenfluramine administration on indices of monoamine function in rat brain: Pharmacokinetic, dose response, regional specificity, and time course data
9. Dexfenfluramine neurotoxicity in brains from non-human primates
10. Dexfenfluramine and serotonin neurotoxicity: Further preclinical evidence that clinical caution is indicated
11. Neurobiology of the anorectic drug fenfluramine
12. On the in vivo and in vitro actions of fenfluramine and its derivatives on central monoamine neurons, especially 5-hydroxytryptamine neurons, and their relation to the anorectic activity of fenfluramine
13. The mechanism of action of fenfluramine
14. Serotonin release estimated by transcortical dialysis in freely-moving rats
15. Fenfluramine administered systemically or locally increases extracellular serotonin in the lateral hypothalamus as measured by microdialysis
16. p-Chloroamphetamine (PCA), 3,4-methylenedioxymethamphetamine (MDMA), and d-fenfluramine pretreatment attenuates d-fenfluramine-evoked release of 5-HT in vivo
17. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine, and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine
18. Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters
19. 2+-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylenedioxy-methamphetamine, p-chloroamphetamine, and (+)-fenfluramine
20. Mechanisms of biogenic amine transporters
21. Fenfluraminebrain serotonin
22. Long-term effects of fenfluramine on central serotonergic mechanisms
23. Fluoxetine attenuates the d,l-fenfluramine-induced increase in extracellular serotonin as measured by in vivo microdialysis
24. Endogenously produced 5,6-dihydroxytryptamine may mediate the neurotoxic effects of parachloroamphetamine
25. Non-neurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine
26. Medicinal chemistry and structure-activity relationships
27. Behavioral, biochemical, and neurotoxicological actions of the α-ethyl homologue of p-chloroamphetamine
28. 3H]Monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues
29. Serotonin-releasing effects of substituted piperazines in vitro
30. 5-HT transporter is an additional site of action for the 5-HT agonists RU 24969 and TFMPP
31. Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats
32. Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain
33. GBR12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat
34. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: Therapeutic implications
35. Identification of a GBR12935 homolog, LR1111, which is over 4000-fold selective for the dopamine transporter, relative to serotonin and norepinephrine transporters
36. Functional consequences of central serotonin depletion produced by repeated fenfluramine administration in rats
37. 125I]RTI- 55
38. Dexfenfluramine: A review of its pharmacological properties and therapeutic potential in obesity
39. m-Chlorophenylpiperazine as a probe of serotonin function
40. Long-term administration of m-chlorophenylpiperazine (mCPP) to rats induces changes in serotonin receptor binding, dopamine levels, and locomotor activity without altering prolactin and corticosterone secretion
41. Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: Uptake inhibition versus release
42. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: Sibutramine is a reuptake inhibitor
43. Substituted piperazine and indole compounds increase extracellular serotonin in rat diencephalon as determined by in vivo microdialysis
44. Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential
45. 5-Hydroxy-3-ethylamino-2-oxindole is not formed in rat brain following a neurotoxic dose of methamphetamine: Evidence that methamphetamine does not induce the hydroxy radical-mediated oxidation of serotonin
46. The serotonin agonist m-chlorophenylpiperazine (mCPP) binds to serotonin transporter sites in human brain
47. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates: Implications for primary pulmonary hypertension
48. 1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in human brain
49. Interaction of arylpiperazines with 5-HT(1A), 5-HT(1B), 5-HT(1C), and 5-HT(1D) receptors: Do discriminatory 5-HT(1B) receptor ligands exist?
50. 2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats
51. 2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: Reversal by L-Dopa
52. m-CPP: A tool for studying behavioral responses associated with 5-HT(1C) receptors
53. Antagonism of vascular serotonin receptors by m-chlorophenylpiperazine and m-trifluoromethylphenylpiperazine
54. 2 and 5-HT(1C) receptors
55. Reduction of food intake by manipulation of central serotonin
56. The appetite suppressant d-fenfluramine induces apoptosis in human serotonergic cells
57. Comparative serotonin neurotoxicity of the stereoisomers of fenfluramine and norfenfluramine
58. Disposition and pharmacological effects of m-chlorophenylpiperazine in rats
59. Single- and multiple-dose kinetics of d-fenfluramine in rats given anorectic and toxic doses
60. Fenfluramine and norfenfluramine levels in brain microdialysate, brain tissue, and plasma of rats administered doses of d-fenfluramine known to deplete 5-hydroxytryptamine levels in brain